Atara Biotherapeutics (NASDAQ:ATRA) Releases Earnings Results, Beats Estimates By $2.63 EPS

Atara Biotherapeutics (NASDAQ:ATRA) released its earnings results on Friday. The biotechnology company reported ($1.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.82) by $2.63, Zacks reports.

Atara Biotherapeutics Stock Performance

ATRA stock traded up $0.10 on Friday, reaching $6.90. The company had a trading volume of 33,198 shares, compared to its average volume of 255,656. The company’s fifty day moving average is $9.85 and its 200 day moving average is $9.71. The company has a market cap of $39.74 million, a P/E ratio of -0.27 and a beta of 0.46. Atara Biotherapeutics has a 1 year low of $5.40 and a 1 year high of $20.81.

Analysts Set New Price Targets

ATRA has been the topic of several research analyst reports. HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a research report on Tuesday, January 28th. RODMAN&RENSHAW lowered shares of Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 21st. Canaccord Genuity Group reduced their price target on shares of Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, January 17th. TD Cowen upgraded Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, November 29th. Finally, Rodman & Renshaw began coverage on Atara Biotherapeutics in a report on Friday, December 20th. They set a “buy” rating and a $25.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $17.75.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.